Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients

Journal of Medical Genetics

Volumn 52, Issue 10, 2015, Pages 699-705

  Hexter, Adam ^a   Jones, Adrian ^b   Joe, Harry ^b   Heap, Laura ^a   Smith, Miriam J ^c   Wallace, Andrew J ^a   Halliday, Dorothy ^d   Parry, Allyson ^d   Taylor, Amy ^e   Raymond, Lucy ^e   Shaw, Adam ^f   Afridi, Shazia ^f   Obholzer, Rupert ^f   Axon, Patrick ^e   King, Andrew T ^g,i   Friedman, Jan M ^b,h   D Gareth R, ^a,c   Burnet, Neil ⁱ   Donnelly, Neil ⁱ   Durie Gair, Juliette ⁱ   English, Martin ⁱ   Folland, Nicola ⁱ   Foweraker, Karen ⁱ   Harris, Fiona ⁱ   Harris, Frances ⁱ   Heney, David ⁱ   Jeffries, Sarah ⁱ   Jena, Raj ⁱ   Knight, Richard ⁱ   Lamb, Tamara ⁱ   Macfarlane, Robert ⁱ   Mannion, Richard ⁱ   Nicholson, James ⁱ   Price, Richard ⁱ   Rands, Ella ⁱ   Sanghera, Paul ⁱ   Scoffings, Daniel ⁱ   Tysome, James ⁱ   Ferner, Rosalie E ⁱ   Hammond, Chris ⁱ   Lascelles, Karine ⁱ   Nunn, Terry ⁱ   Saeed, Shakeel ⁱ   Swampillai, Angela ⁱ   Thomson, Suki ⁱ   Walsh, Daniel ⁱ   Williams, Victoria ⁱ   Wood, Sue ⁱ   Anup, Raji ⁱ   Duff, Chris ⁱ   Evans, D Gareth ⁱ   Freeman, Simon R ⁱ   Howie, Emma ⁱ   Huson, Susan M ⁱ   Jarvis, Nicola ⁱ   Kamaly Asi, Ian ⁱ   Kellett, Mark ⁱ   Kilday, John Paul ⁱ   Lloyd, Simon K ⁱ   Malluci, Connor ⁱ   Mawman, Deborah ⁱ   McBain, Catherine ⁱ   Mills, Sam ⁱ   O'Driscoll, Martin ⁱ   Patel, Sonia ⁱ   Perry, Mary ⁱ   Rutherford, Scott A ⁱ   Scott Kitching, Vilka ⁱ   Stivaros, Stavros M ⁱ   Thomas, Owen ⁱ   Vassallo, Grace ⁱ   Ward, Charlotte L ⁱ   Blesing, Claire ⁱ   Cogswell, Lucy ⁱ   Dalton, Louise ⁱ   Dodridge, Caroline ⁱ   Elston, John ⁱ   Giele, Henk ⁱ   Hanemann, C Oliver ⁱ   Howard, Wendy ⁱ   Johnson, David ⁱ   Kerr, Richard ⁱ   Laws, Avianna ⁱ   Lee, James ⁱ   Mace, Elle ⁱ   May, Anne ⁱ   Milford, Chris ⁱ   Pretorius, Peter ⁱ   Ramsden, James ⁱ   Redman, Caroline ⁱ   Warner, Nicola ⁱ   Wilson, Shaun ⁱ   more..

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; EXON; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MISSENSE MUTATION; MOLECULAR GENETICS; MORTALITY; MOSAICISM; NEUROFIBROMATOSIS TYPE 2; PRIORITY JOURNAL; UNITED KINGDOM; GENETIC ASSOCIATION STUDY; GENETICS; KAPLAN MEIER METHOD; MUTATION; NEUROFIBROMATOSIS 2; PRESCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, NEUROFIBROMATOSIS 2; GENETIC ASSOCIATION STUDIES; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MUTATION; NEUROFIBROMATOSIS 2; UNITED KINGDOM;

EID: 84946477803     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2015-103290     Document Type: Article

References (46)

1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010;152A:327-32.
2. Evans DG. Neurofibromatosis 2. In: Pagon RA, Adam MP, Ardinger HH, et al. eds. GeneReviews® . Seattle, WA: University of Washington, Seattle, 1993-2015.http:// www.ncbi.nlm.nih.gov/books/NBK1201/
3. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett 2014;588:2743-52.
4. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 2013;114:257-62.
5. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
6. Evans DG, Ramsden R, Huson SM, Harris R, Lye R, King TT. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol 1993;107:401-6.
7. Bourn D, Carter SA, Evans DG, Goodship J, Coakham H, Strachan T. A mutation in the Neurofibromatosis type 2 tumour suppressor gene giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 1994;55:69-73.
8. Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71:715-23.
9. Gutmann DH, Geist RT, Xu H-M, Kim JS, Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 1998;7:335-45.
10. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Fünsterer C, Mautner VF. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-8.
11. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.
12. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-39.
13. Selvanathan SK, Shenton A, Ferner R, Wallace AJ, Huson SM, Ramsden RT, Evans DG. Further genotype-phenotype correlations in neurofibromatosis 2. Clin Genet 2010;77:163-70.
14. Bourn D, Carter SA, Mason S, Evans DG, Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Molec Genet 1994;5:813-16.
15. Evans DG, Trueman L, Wallace A, Mason S, Strachan T. Genotype phenotype correlations in neurofibromatosis 2 (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
16. Watson CJ, Gaunt L, Evans G, Patel K, Harris R, Strachan T. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet 1993;2:701-4.
17. Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lázaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 2005;42:540-6.
18. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759-65.
19. Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Pichert G, Wallace A. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/ bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007;44:424-8.
20. Zhao Y, Kumar RA, Baser ME, Evans DG, Wallace A, Kluwe L, Mautner VF, Parry DM, Rouleau GA, Joe H, Friedman JM. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol 2002;23:245-59.
21. Mosteller F, Tukey JW. Data analysis and regression: a second course in statistics. Reading, MA: Addison-Wesley, 1977.
22. Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DG. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 2011;13:576-81.
23. Aboukais R, Zairi F, Bonne NX, Baroncini M, Schapira S, Vincent C, Lejeune JP. Causes of mortality in neurofibromatosis type 2. Br J Neurosurg 2014;25:1-4.
24. Otsuka G, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 2003;99:480-3.
25. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 2002;96:217-22.
26. Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 2002;96:223-8.
27. Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 2004;25:811-17.
28. Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, Lonser RR, Asthagiri AR. Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 2012;117:109-17.
29. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
30. Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 2006;141:1068-77.
31. Baser ME, Wallace AJ, Strachan T, Evans DG. Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2. J Med Genet 2000;37:542-3.
32. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DG. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63.
33. Evans DG, Wallace A. An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J Med Genet 2009;46:792.
34. Mautner VF, Baser ME, Kluwe L. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 1996;98:203-6.
35. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-33.
36. Laulajainen M, Melikova M, Muranen T, Carpén O, Grönholm M. Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity. J Cell Mol Med 2012;16:2161-75.
37. Chang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 2002;79:63-76.
38. Grönholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpén O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci 1999;112:895-904.
39. Meng JJ, Lowrie DJ, Sun H, Dorsey E, Pelton PD, Bashour AM, Groden J, Ratner N, Ip W. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. J Neurosci Res 2000;62:491-502.
40. Surace EI, Haipek CA, Gutmann DH. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 2004;23:580-7.
41. Laulajainen M, Muranen T, Nyman TA, Carpén O, Grönholm M. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia 2011;13:643-52.
42. Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Evans DG. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011;48:261-5.
43. Abo-Dalo B, Kutsche K, Mautner V, Kluwe L. Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes. Genes Chromosomes Cancer 2010;49:171-5.
44. Hulsebos TJ, Kenter S, Verhagen WI, Baas F, Flucke U, Wesseling P. Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathol 2014;128:439-48.
45. Evans DG, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005;19:5-12.
46. Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M. Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clin Cancer Res 2009;15:5032-9.